New and Noteworthy Information—August 2014

Upsher-Smith Laboratories (Maple Grove, Minnesota) announced that Qudexy XR (topiramate) extended-release capsules are now available in the United States. Qudexy XR, a broad-spectrum, once-daily antiepileptic drug is engineered to deliver a smooth pharmacokinetic profile. The FDA approved Qudexy XR in March 2014 as an initial monotherapy in patients 10 and older with primary generalized tonic-clonic seizures and partial-onset seizures. The drug also was approved as adjunctive therapy in patients 2 and older with primary generalized tonic-clonic seizures, partial-onset seizures, and seizures associated with Lennox-Gastaut syndrome. Overall, results from Upsher-Smith’s phase III trial showed that Qudexy XR is generally well tolerated and effective.

Transplanted brain cells producing dopamine remain viable in patients with Parkinson’s disease for several years, according to a study published June 26 in Cell Reports. The study included five patients with Parkinson’s disease who received transplants of fetal tissue-derived, dopamine-producing neurons four to 14 years earlier. Their transplanted dopamine neurons showed no signs of Parkinson’s disease–associated deterioration and appeared healthy. Researchers believe the findings provide further support for stem cells as a source for transplant-ready dopamine neurons. The investigators noted that the neuronal transplant has proven to be a durable treatment for many patients with Parkinson’s disease, with some improving for years without a need for standard medications. The study authors called the new finding “extremely encouraging,” adding that the long life of the transplanted neurons bodes well “for advancing [the technique] as a restoration therapy for Parkinson’s disease.”

Women may recover more quickly than men after a concussion, according to a study published online ahead of print May 6 in Radiology. Researchers examined the medical records and imaging results of 69 patients diagnosed with mild traumatic brain injury (TBI) between 2006 and 2013. The cohort included 47 men, 22 women, and 21 controls (10 men; median age of men, 17; median age of women, 16). Of the 47 men with TBI, 32 (68%) were injured while playing a sport, as were 10 of the 22 women (45%). Although all participants underwent the same evaluation, diffusion tensor imaging scans revealed that compared with the female patients with mild TBI, the male patients with mild TBI had significantly decreased uncinate fasciculus fractional anisotropy values. The average recovery time for all patients with concussion was 54 days. However, compared with women, who recovered in an average of 26.3 days, recovery was significantly longer for men (66.9 days).

Patients with mesial temporal lobe epilepsy who cannot be controlled with medication can now opt for a minimally invasive laser procedure performed under MRI guidance, according to a study published in the June issue of Neurosurgery. Researchers used an MRI-guided stereotactic laser amygdalohippocampotomy in 13 adult patients with epilepsy (median age, 24). During this procedure, a saline-cooled fiber-optic laser probe was targeted at the amygdalohippocampal complex. Using real-time MRI guidance, a neurosurgeon pinpointed the area of the brain responsible for seizure activity and destroyed this tissue without harming nearby brain tissue. Sixty percent of the amygdalohippocampal complex was destroyed, and the average length of the ablated area was 2.5 cm. “Such minimally invasive techniques may be more desirable to patients and result in increased use of epilepsy surgery among the large number of medically intractable epilepsy patients,” according to the investigators.

Researchers identified 10 proteins in the blood that can predict the onset of Alzheimer’s disease, according to a study published online ahead of print July 3 in Alzheimer’s & Dementia. In the international study of 1,148 individuals (220 with mild cognitive impairment [MCI], 452 elderly controls without dementia, and 476 with Alzheimer’s disease), blood samples were analyzed for 26 proteins previously associated with Alzheimer’s disease. Investigators found 16 of the 26 proteins to be strongly associated with brain shrinkage in Alzheimer’s disease or MCI. The researchers conducted a second series of tests to establish which of these proteins could predict the progression from MCI to Alzheimer’s disease. The study authors identified a combination of 10 proteins capable of predicting whether individuals with MCI would develop Alzheimer’s disease within a year with 87% accuracy. “Memory problems are common, but the challenge is identifying who is likely to develop dementia,” according to the researchers.

An international team of researchers has reviewed the diagnostic criteria for Alzheimer’s disease developed by the International Working Group (IWG) and US National Institute on Aging–Alzheimer’s Association, according to a study published in the June issue of Lancet Neurology. The team considered the strengths and weakness of the IWG criteria and proposed advances to improve the diagnostic framework. The investigators asserted that the diagnosis of Alzheimer’s disease can be simplified by requiring the presence of an appropriate clinical Alzheimer’s disease phenotype (typical or atypical) and a pathophysiologic biomarker consistent with the presence of Alzheimer’s pathology. “We propose that downstream topographic biomarkers of the disease, such as volumetric MRI and fluorodeoxyglucose PET, might better serve in the measurement and monitoring of the course of disease,” the team stated